MetaVia Inc. (MTVA)
 NASDAQ: MTVA · Real-Time Price · USD
 0.9901
 +0.0153 (1.57%)
  Oct 31, 2025, 11:50 AM EDT - Market open
MetaVia Employees
MetaVia had 9 employees as of December 31, 2024. The number of employees increased by 1 or 12.50% compared to the previous year.
Employees 
 9
Change (1Y) 
 1
Growth (1Y) 
 12.50%
Revenue / Employee 
 n/a
Profits / Employee 
 -$2,054,556
Market Cap 
23.96M
Employees Chart
Employees History
| Date | Employees | Change | Growth | 
|---|---|---|---|
| Dec 31, 2024 | 9 | 1 | 12.50% | 
| Dec 31, 2023 | 8 | 6 | 300.00% | 
| Dec 31, 2022 | 2 | -3 | -60.00% | 
| Dec 31, 2021 | 5 | -2 | -28.57% | 
| Dec 31, 2020 | 7 | -5 | -41.67% | 
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | 
Related Stocks
| Company Name | Employees | 
|---|---|
| UnitedHealth Group | 400,000 | 
| Johnson & Johnson | 138,100 | 
| Thermo Fisher Scientific | 125,000 | 
| Abbott Laboratories | 114,000 | 
| AstraZeneca | 92,900 | 
| Novo Nordisk | 77,349 | 
| Novartis AG | 75,883 | 
| Merck & Co. | 75,000 | 
MTVA News
- 4 days ago - MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting - PRNewsWire
- 11 days ago - MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025 - PRNewsWire
- 17 days ago - MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference - PRNewsWire
- 2 months ago - MetaVia to Present at Upcoming Investor and Industry Conferences - PRNewsWire
- 3 months ago - MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient - PRNewsWire
- 3 months ago - MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241 - PRNewsWire
- 4 months ago - MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose - PRNewsWire